Safety and Feasibility of Intraoperative Visualization With Cytalux in Children (NCT06235125)
A Pilot Study of Near-Infrared Imaging Using the Novel Imaging Agent Cytalux for Adolescent Patients With Metastatic Osteosarcoma Undergoing Pulmonary Metastasectomy
🩺 Plain-English Summary (8th-Grade Level)
Pediatric subjects aged 6-17 with biopsy confirmed cancer and imaging findings suspicious for pulmonary metastatic disease scheduled to undergo pulmonary metastasectomy via and open or minimally invasive approach.
Who can join: Review the eligibility criteria below.
Location: Ann & Robert H. Lurie Children's Hospital — Chicago, Illinois
Age range: 6 Years to 17 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Ann & Robert H. Lurie Children's Hospital — Chicago, Illinois
📞 Contact the Study Coordinator
Phone: (312) 227-4210
Email: tlautz@luriechildrens.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Osteosarcoma
- Chemotherapy Resistance in Osteogenic Sarcoma and Other Solid Tumors — New York, New York
- SARC038: Phase 2 Study of Regorafenib and Nivolumab in Osteosarcoma — Los Angeles, California
- Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma — Birmingham, Alabama
- Olaparib With Ceralasertib in Recurrent Osteosarcoma — San Francisco, California
- A Phase I Feasibility And Safety Study of Fluorescein-Specific (FITC-E2) CAR T Cells In Combination With Parenterally Administered Folate-Fluorescein (UB-TT170) For Osteogenic Sarcoma — Seattle, Washington
- iC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma and Neuroblastoma — Houston, Texas
Explore by condition: All Osteosarcoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.